Alnylam showcases late-breaking heart treatment, hypertension findings at ESC 2026
Alnylam will present new clinical and real-world data across its transthyretin-mediated amyloidosis and hypertension programs at ESC Congress 2026 in Munich on 28-31 August 2026. Presentations include late-breaking pre-specified analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) asses
<p>Alnylam will present new clinical and real-world data across its transthyretin-mediated amyloidosis and hypertension programs at ESC Congress 2026 in Munich on 28-31 August 2026. Presentations include late-breaking pre-specified analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) asses</p>